Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Montelukast Sodium

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Montelukast Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,129Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA finds widely used asthma drug impacts the brain
    US FDA finds widely used asthma drug impacts the brain

    23 Nov 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/mercks-former-asthma-blockbuster-singulair-could-be-linked-to-mental-health-problems-reuters

    BIOSPACE
    23 Nov 2024
    Share Share
    IntelGenx Reports Preliminary Results For Montelukast VersaFilm In Alzheimer's
    IntelGenx Reports Preliminary Results For Montelukast VersaFilm In Alzheimer's

    03 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/03/2908117/0/en/IntelGenx-Obtains-Preliminary-Efficacy-Results-for-the-BUENA-Montelukast-VersaFilm-Phase-2a-Clinical-Trial-in-Patients-with-Mild-to-Moderate-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    03 Jul 2024
    Share Share
    New York attorney general urges stronger safety warning on asthma drug Singulair
    New York attorney general urges stronger safety warning on asthma drug Singulair

    23 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/new-york-attorney-general-urges-stronger-safety-warning-asthma-drug-singulair-2024-02-23/

    REUTERS
    23 Feb 2024
    Share Share
    Enforcement Report - Week of November 15, 2023
    Enforcement Report - Week of November 15, 2023

    15 Nov 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-15-2023-17266.pdf

    FDA
    15 Nov 2023
    Share Share
    Merck accused of downplaying early evidence of drug’s brain impact
    Merck accused of downplaying early evidence of drug’s brain impact

    27 Jun 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-accused-downplaying-early-evidence-drugs-brain-impact-2023-06-26/

    REUTERS
    27 Jun 2023
    Share Share
    Health Canada Issues Recall of Pro Doc Ltée's Montelukast chewable tablet; Out of specification
    Health Canada Issues Recall of Pro Doc Ltée's Montelukast chewable tablet; Out of specification

    12 May 2023

    // HEALTH CANADA

    https://recalls-rappels.canada.ca/en/alert-recall/montelukast-chewable-tablet-out-specification

    HEALTH CANADA
    12 May 2023
    Share Share